RoundTable Healthcare Partners announces CEO of its portfolio co.
LAKE FOREST, Ill. A private-equity firm that focuses on the healthcare industry has appointed two senior healthcare executives.
RoundTable Healthcare Partners announced Wednesday the appointment of Christopher Worrell as CEO of RoundTable portfolio company CorePharma and appointed Greg Baumli as SVP manufacturing. The company said the new appointments would add to its industry expertise and operating capabilities.
“I am excited to work with the CorePharma team,” Worrell said in a statement. “CorePharma has developed a diversified portfolio of generic pharmaceutical products with an impressive pipeline of new products in various stages of development.”
Bristol-Myers Squibb announces executive changes
NEW YORK Drug maker Bristol-Myers Squibb announced a wave of executive appointments Wednesday as part of what it called a transformation to a “next-generation” biopharmaceutical leader.
The company appointed Lamberto Andreotti as president and COO and elected him to the board of directors, also placing him on the newly formed executive committee with chairman and CEO James Cornelius. Elliott Sigal became EVP, chief science officer and president research and development and will oversee Bristol’s research, discovery and development functions. Jean-Marc Huet was promoted to EVP and CFO and will also oversee the areas of strategy and productivity.
“This group will chart the future for Bristol-Myers Squibb,” Cornelius said in a statement. “Our transformation over the past 15 months has been swift and seamless, and we will continue to move forward as a company purely focused on helping patients prevail against serious disease.”
Bristol also named Anthony Hooper as president for the Americas, Beatrice Cazala as president for global commercialization and Europe, John Celentano as president for emerging markets and the Asia-Pacific region, Giovanni Caforio as SVP global and United States oncology and Carlo De Notaristefani as president for technical operations and global support functions.
Vertex Pharmaceuticals to acquire ViroChem Pharma
CAMBRIDGE, Mass. A company developing a drug for treating hepatitis C will add two more drugs for the disease to its portfolio by acquiring a company based in Quebec.
Vertex Pharmaceuticals announced Tuesday that it would acquire ViroChem Pharma, a privately held company, for $100 million in cash and 9.9 million shares of Vertex common stock.
Vertex is developing telaprevir, a protease inhibitor for fighting the hepatitis C virus in phase 3 development, while ViroChem is developing two polymerase inhibitors.
“This acquisition significantly strengthens our pipeline in hepatitis C by bringing together Vertex’s telaprevir, our HCV protease inhibitor in registration studies, with the HCV non-nucleoside polymerase inhibitors being developed by ViroChem,” Vertex CEO Joshua Boger said in a statement. “Through this acquisition, we’re well-positioned as a leader in the development of HCV therapies.”